Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Tim Mayleben Named President And CEO Of Esperion Therapeutics



        Tim Mayleben Named President And CEO Of Esperion Therapeutics

Founder Roger Newton becomes executive chairman and chief scientific officer.

PR Newswire

PLYMOUTH, Mich., Jan 4, 2013

PLYMOUTH, Mich., Jan 4, 2013 /PRNewswire/ -- Esperion Therapeutics, the
leading developer of small molecule therapies for the treatment of
cardiometabolic disorders, today announced that Tim Mayleben has been named
president and CEO of the company.  Roger Newton, Ph.D., FAHA, who is the
founder of Esperion and has been serving as its president and CEO, will become
executive chairman and chief scientific officer.

Most recently, Mr. Mayleben was president and CEO at Aastrom Biosciences. 
Previously, he was an advisor to life science and healthcare companies through
his advisory and investment firm, ElMa Advisors, president, COO and a director
of NightHawk Radiology, and chief operating officer and CFO of the original
Esperion Therapeutics, which Dr. Newton also founded.  While at Esperion, Mr.
Mayleben raised more than $200 million in venture and institutional equity
capital and negotiated the sale of Esperion to Pfizer for $1.3 billion in
February 2004.

"We've made tremendous progress with ETC-1002, our novel small molecule LDL-C
lowering therapy for treating statin-intolerant and statin-resistant
patients.  I'm excited that Tim is re-joining me at the new Esperion.  He's
the ideal person to help guide Esperion through the next phases of our growth
and development.  At the original Esperion, Tim's outstanding business acumen
and judgment played a critical role in our success at every stage.  We are
very pleased that he will be joining us as our president and CEO," said Dr.
Newton.

Esperion's most advanced product candidate, ETC-1002, is in Phase 2 clinical
trials for patients with hypercholesterolemia and other cardiometabolic risk
factors.  ETC-1002 is a small-molecule metabolic regulator of imbalances in
lipid and carbohydrate metabolism and inflammation.  It is being developed to
address the underlying causes of metabolic diseases and reduce multiple risk
factors associated with them.  In preclinical and clinical studies to date,
treatment with ETC-1002 has been shown to be safe and well-tolerated while
producing statin-like reductions in LDL-C and inflammatory markers. 

"Under Roger's leadership, the development of Esperion's lead compound
ETC-1002 has advanced rapidly and shown tremendous clinical and therapeutic
potential.  I am excited to be working with Roger again and look forward to
helping the Esperion team realize the full potential of ETC-1002 and our
broader portfolio of lipid-regulating therapies to treat cardiometabolic
diseases. I share their passion and commitment to this important therapeutic
area and believe the next few years will be a very exciting and rewarding time
for Esperion," Mr. Mayleben said.

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the
treatment of cardiometabolic diseases. The company's lead product candidate,
ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is
being evaluated in multiple Phase 2 clinical trials for the treatment of
hypercholesterolemia and other cardiometabolic risk factors.  Esperion intends
to commercialize innovative, first-in-class therapies focused on enhancing
lipid regulation, addressing statin intolerance and improving overall
cardiometabolic health. For more information, please visit www.esperion.com.

SOURCE Esperion Therapeutics

Website: http://www.esperion.com
Contact: Andrea Coan, Berry & Company Public Relations, +1-212-253-8881,
acoan@berrypr.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement